Enveric Biosciences (NASDAQ: ENVB) shares new Q3 2025 investor presentation

Rhea-AI Filing Summary

Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an Investor Presentation for Q3 2025. Management plans to post these materials on the company’s website and may use them in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.

The Investor Presentation is furnished as Exhibit 99.1 to this report and is also accessible through Enveric’s investor relations webpage. The company specifies that this information is being “furnished” under Regulation FD, meaning it is not treated as filed for liability purposes under the Exchange Act unless specifically incorporated into another filing.

false 0000890821 0000890821 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934

August 29, 2025

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38286		95-4484725
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

Enveric Biosciences, Inc.

4851 Tamiami Trail N, Suite 200

Naples, FL 34103

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (239) 302-1707

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the ExchangeAct (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the ExchangeAct (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the ExchangeAct (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of theAct:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐

Item 7.01 Regulation FD Disclosure.

Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about August 29, 2025. From time to time thereafter, the Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others with an interest in the Company and its business.

A copy of the Investor Presentation is furnished as Exhibit 99.1 to this report and incorporated here by reference. A copy of the Investor Presentation is also available via the Company’s website at https://www.enveric.com/investors/events/. Materials on the Company’s website are not part of or incorporated by reference into this report.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the ExchangeAct, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Investor Presentation Q3 2025 (furnished pursuant to Item 7.01)
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 29, 2025	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph Tucker
		Chief Executive Officer

FAQ

What did Enveric Biosciences (ENVB) disclose in this 8-K filing?

Enveric Biosciences disclosed that it has prepared an Investor Presentation for Q3 2025 and that management intends to make it available on the company’s website and use it in meetings with investors and other stakeholders.

Where can investors access Enveric Biosciences’ Q3 2025 Investor Presentation?

The Q3 2025 Investor Presentation is furnished as Exhibit 99.1 to the report and is also available on Enveric’s investor relations website at https://www.enveric.com/investors/events/.

How is the Enveric Biosciences Investor Presentation treated under SEC rules?

The company states that the Investor Presentation, furnished under Item 7.01 Regulation FD Disclosure, is considered “furnished” and not “filed” for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference in another filing.

What exhibit numbers are included in this Enveric Biosciences 8-K?

The filing includes Exhibit 99.1, the Investor Presentation for Q3 2025, and Exhibit 104, the cover page interactive data file formatted as Inline XBRL.

Who signed this Enveric Biosciences 8-K report?

The report was signed on behalf of Enveric Biosciences, Inc. by Joseph Tucker, who is identified as the company’s Chief Executive Officer.

For what purposes might Enveric’s Q3 2025 Investor Presentation be used?

The company notes that it may use the Investor Presentation, possibly with modifications, in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others interested in the business.